EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non‐small cell lung cancer
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr et al. · International Journal of Cancer · 2018
In order to identify anaplastic lymphoma kinase‐driven non‐small cell lung cancer (ALK + NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule‐associated protein‐like 4 ( EML4 )‐ ALK fusion variants V1, V2 and V3 as detected by next‐generation sequencing or reverse transcription‐polymerase chain reaction ( n = 67). Progression under tyrosine kinase inhibitor (TKI) treatment was evaluated both according to Response Evaluation Criteria in Solid Tumors (RECIST) and by the need to change systemic therapy. EML4‐ALK fusion variants V1, V2 and V3 were found in 39%, 10% and 51% of cases, respectively. Patients with V3‐driven tumors had more metastatic sites at diagnosis than cases with the V1 and V2 variants (mean 3.3 vs . 1.9 and 1.6, p = 0.005), which suggests increased disease aggressiveness. Furthermore, V3‐positive status was associated with earlier failure after treatment with first and second‐generation ALK TKI (median progression‐free survival [PFS] by RECIST in the first line 7.3 vs . 39.3 months, p = 0.01), platinum‐based combination chemotherapy (median PFS 5.4 vs . 15.2 months for the first line, p = 0.008) and cerebral radiotherapy (median brain PFS 6.1 months vs . not reached for cerebral radiotherapy during first‐line treatment, p = 0.028), and with inferior overall survival (39.8 vs . 59.6 months in median, p = 0.017). Thus, EML4‐ALK fusion variant V3 is a high‐risk feature for ALK + NSCLC. Determination of V3 status should be considered as part of the initial workup for this entity in order to select patients for more aggressive surveillance and treatment strategies.
Cited by 139 works. doi:10.1002/ijc.31275 Open-access PDF
Authors
- Petros Christopoulos
- Volker Endris
- Farastuk Bozorgmehr
- Mei Elsayed
- Martina Kirchner
- Jonas Ristau
- Ivo Buchhalter
- Roland Penzel
- Felix J.F. Herth
- Claus Peter Heußel
- Martin Eichhorn
- Thomas Muley
- Michael A. Meister
- Jürgen R. Fischer
- Stefan Rieken
- Arne Warth
- Helge G. Bischoff
- Peter Schirmacher
- Albrecht Stenzinger
- Michael Thomas
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- The anaplastic lymphoma kinase in the pathogenesis of cancer
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
- Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
- Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification